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April 24, 2012:1570–3Second, if the lower cutoff point is used only to rule out infarction,
how many patients will be discharged by this new approach? Body et
al. showed that 28% of the cohort had negative troponin, ensuring no
infarction. However, the study did not report howmany of those were
really discharged. From those patients, some could have very typical
chest pain, characterizing unstable angina; some could have ischemic
electrocardiogram changes; and others could have other serious causes
of chest pain that prevented discharge. Therefore, a negative troponin
does not necessarily mean discharge and the actual number of patients
in which the troponin result helped the decision is not clear in the
paper.
The universal definition of infarction takes the 99th percentile
of troponin as the cutoff point (2), providing good diagnostic
accuracy (85% sensitivity and 82% specificity) (1). Before trading
this accuracy for a higher sensitivity at the expense of specificity
(so-called D-dimer approach), clinical evidence should demon-
strate a real advantage over the traditional way of troponin
interpretation. The definitive level of evidence will be ideally
provided by randomized clinical trials comparing the 2 strategies.
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Figure 1 Algorithm for the Diagnosis of AMI
AMI  acute myocardial infarction; hs-cTnT  high-sensitivity cardiac troponin T.EFERENCES
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Reply
We thank Drs. Kavsak and Worster and Drs. Correia and
Noya-Rabelo for their interest in our paper (1). We understand the
concerns of Drs. Correia and Noya about the specificity of our
proposed use of high-sensitivity cardiac troponin T (hs-cTnT) (1).
This approach may have more in common with the use of brain
natriuretic peptide than D-dimer. Some levels of brain natriuretic
peptide are diagnostic of either the presence of heart failure or its
absence (2). Other patients have levels that are not sufficiently high or
low enough to be diagnostic and require additional testing. This is the
case with hs-cTnT. Some patients will have acute myocardial infarc-
tion (AMI) ruled out immediately, whereas others still require serial
testing to establish a diagnosis, as per current practice (Fig. 1). This
will maintain overall specificity while avoiding serial testing in a large
group, reducing emergency department crowding and its negative
consequences while facilitating accurate patient evaluation and care.
Not all patients with an initial hs-cTnT 3 ng/l will be eligible
for early discharge. We strongly believe that hs-cTnT is an adjunct
to care and not a substitute for clinical evaluation. For example, 22
(11.3%) of the patients with hs-cTnT 3 ng/l had ischemic
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April 24, 2012:1570–3electrocardiogram changes. Physicians are unlikely to immediately
discharge that group. However, our findings suggest that AMI
remains extremely unlikely and alternative diagnoses can be con-
sidered at an early stage.
Drs. Kavsak and Worster question the diagnostic performance
of hs-cTnT using the limit of detection (LoD) (5 ng/l) rather than
the limit of blank (LoB) (3 ng/l) as a cutoff. At the LoD cutoff, 272
(38.7%) patients would have had AMI immediately “ruled out” in
our prospective cohort study. Three AMIs would have been
missed. Thus, sensitivity fell to 97.7% (95% confidence interval
[CI]: 93.4% to 99.5%) with a negative predictive value of 98.9%
(95% CI: 96.8% to 99.8%). In our subsequent evaluation of
hs-cTnT in clinical practice, 195 (21.3%) patients had an initial
hs-cTnT below the LoD and only 2 developed elevated levels
(14 ng/l) on subsequent testing. Thus, sensitivity was 99.7%
(95% CI: 98.8% to 100.0%) with negative predictive value 99.0%
(95% CI: 96.3% to 99.9%). It remains to be decided whether these
results can be confirmed in other datasets and whether the clinical
community will find these results acceptable.
Recently, there has been discussion about reporting only down
to the LoD rather than to the LoB. Our findings may influence
that discussion. If the LoB provides important clinical data, this
fact should be considered. Indeed, we reported a sensitivity of
100.0% at the LoB in our cohort study (Reichlin et al. [3] and,
ore recently, Christ et al. [4] also reported the same sensitivity)
nd a 99.8% value in a cohort from clinical practice. Our findings
ertainly suggest that further work is necessary to improve the
nalytical precision of troponin assays at that level.
In our cohort study, samples were not repeated when hemolysis
as present, although we understand that hemolysis can lower
s-cTnT levels (4). Fifty-four (7.7%) of the samples in our cohort
tudy showed some degree of hemolysis. Twelve of those samples
ad values 3 ng/l, which is below the LoB. We would advocate
epeating the sample before excluding AMI at any cutoff whether
t be the LoB or the LoD. No AMIs were missed using this
pproach, although the number of patients affected was small.
Our findings are preliminary. They require further prospective
alidation and subsequent evaluation in a randomized controlled
rial. However, approaches like these are required to move the field
orward by reducing the time taken to exclude AMI. We believe
hat we should, over time, be able to unencumber emergency
epartments by developing innovative approaches for ruling out
MI. Our investigation starts that important work.
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Microvolt T-Wave Alternans
Testing Has a Role in
Arrhythmia Risk Stratification
In one interesting aspect, the letter by Jackson et al. (1) pertains to
risk stratification in general. They suggest that evidence-based
cardiac risk assessment should be an automatic process devoid of
individual clinical judgment. We disagree and maintain that any
risk assessment requires careful interpretation by experienced
physicians. Unfortunately, the Glasgow group misrepresented our
guideline statement (2) not only in this respect.
The presence of abnormal T-wave alternans (TWA) has
demonstrated clinical utility in stratifying risk for malignant
arrhythmias and sudden cardiac death. This derives from
prospective, peer-reviewed studies involving 12,000 patients.
These data clearly show that patients with increased TWA
levels have 2- to 23-fold independently higher risk of serious
outcomes as compared with those with lower TWA levels.
Elevated TWA provides risk information independent of left
ventricular ejection fraction (LVEF), standard clinical variables
(e.g., age and sex), and important cardiovascular risk markers
(e.g., smoking, diabetes, hypertension, and medication usage).
Our assertion, “it is reasonable to consider TWA evaluation
whenever there is suspicion of vulnerability to lethal cardiac
arrhythmias,” concurs with prior statements by the American
Heart Association (3,4), the American College of Cardiology
(3,4), and the National Institutes of Health (5).
As with any risk stratification method, including LVEF, not
all studies are consistent with the overall trend. Specifically, in
the MASTER (Microvolt T-Wave Alternans Testing for Risk
Stratification of Post-Myocardial Infarction Patients) trial and
TWA substudy of SCD-HeFT (Sudden Cardiac Death in
Heart Failure Trial), TWA did not predict appropriate im-
plantable cardioverter-defibrillator (ICD) therapy, sudden car-
diac death, and/or ventricular tachycardia/fibrillation. As dis-
cussed in our document (2), there are plausible explanations for
this departure from the bulk of the literature. Specifically, a
recent systematic review and meta-analysis determined that
